Pediatric high-grade glioma: current molecular landscape and therapeutic approaches
- PMID: 28357536
- DOI: 10.1007/s11060-017-2393-0
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches
Abstract
High-grade pediatric central nervous system glial tumors are comprised primarily of anaplastic astrocytomas (AA, WHO grade III) and glioblastomas (GBM, WHO grade IV). High-grade gliomas are most commonly diagnosed in the primary setting in children, but as in adults, they can also arise as a result of transformation of a low-grade malignancy, though with limited frequency in the pediatric population. The molecular genetics of high-grade gliomas in the pediatric population are distinct from their adult counterparts. In contrast to the adult population, high-grade gliomas in children are relatively infrequent, representing less than 20% of cases.
Keywords: Pediatric astrocytoma; Pediatric brain tumor; Pediatric glioblastoma.
Similar articles
-
Gliomas in Children.Semin Neurol. 2018 Feb;38(1):121-130. doi: 10.1055/s-0038-1635106. Epub 2018 Mar 16. Semin Neurol. 2018. PMID: 29548059 Review.
-
Diffusely infiltrative low-grade gliomas in adults.J Clin Oncol. 2006 Mar 10;24(8):1236-45. doi: 10.1200/JCO.2005.05.2399. J Clin Oncol. 2006. PMID: 16525178 Review.
-
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e305-e316. doi: 10.1016/S1470-2045(20)30064-4. Lancet Oncol. 2020. PMID: 32502457 Review.
-
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.Lancet Oncol. 2020 Jun;21(6):e317-e329. doi: 10.1016/S1470-2045(20)30173-X. Lancet Oncol. 2020. PMID: 32502458 Review.
-
Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).J Neurooncol. 2005 Apr;72(2):179-83. doi: 10.1007/s11060-004-3546-5. J Neurooncol. 2005. PMID: 15925999 Clinical Trial.
Cited by
-
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.Front Immunol. 2021 May 7;12:637146. doi: 10.3389/fimmu.2021.637146. eCollection 2021. Front Immunol. 2021. PMID: 34025646 Free PMC article.
-
Temozolomide and oral etoposide in children with recurrent malignant brain tumors.Drugs Context. 2020 Jun 2;9:2020-3-1. doi: 10.7573/dic.2020-3-1. eCollection 2020. Drugs Context. 2020. PMID: 32547627 Free PMC article. Review.
-
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.Front Oncol. 2021 Jun 8;11:631037. doi: 10.3389/fonc.2021.631037. eCollection 2021. Front Oncol. 2021. PMID: 34168976 Free PMC article. Review.
-
Updates on the 2016 World Health Organization Classification of Pediatric Tumors of the Central Nervous System - a systematic review.Med Pharm Rep. 2021 Jul;94(3):282-288. doi: 10.15386/mpr-1811. Epub 2021 Jul 29. Med Pharm Rep. 2021. PMID: 34430849 Free PMC article. Review.
-
Cancer Predisposition Syndromes Associated With Pediatric High-Grade Gliomas.Front Pediatr. 2020 Nov 12;8:561487. doi: 10.3389/fped.2020.561487. eCollection 2020. Front Pediatr. 2020. PMID: 33282797 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources